Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro

BACKGROUND: Gleevec (aka STI571, Imatinib) is a recently FDA approved anti-tumor drug for chronic myelogenous leukemia. Gleevec binds specifically to BCR-ABL tyrosine kinase and inhibit the tyrosine kinase activity. It cross-reacts with another two important membrane tyrosine kinase receptors, c-kit...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Zhang, Peilin, Gao, Wei Yi, Turner, Steven, Ducatman, Barbara S
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2003
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC149413/
https://ncbi.nlm.nih.gov/pubmed/12537587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-2-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller